


wherein X is  $R_1$ ,  $OR_1$ , or  $SR_1$ ;

wherein  $R_1$  is

- (i) a hydrogen atom;
- (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;
- (iii) a cycloalkyl of 3 to 10 carbon atoms;
- (iv) an aralkyl of 7 to 12 carbon atoms;
- (v) phenyl;
- (vi) substituted phenyl



wherein  $Z_i$ ,  $Z_{ii}$ ,  $Z_{iii}$ ,  $Z_{iv}$  and  $Z_v$  are each independently selected from  $-NO_2$ ,  $-CN$ ,  $-C(=O)-R_1$ ,  $-SO_3H$ , a hydrogen atom, halogen, methyl,  $-OR_x$ , wherein  $R_x$  is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

- (vii) a detectable label molecule; or

- (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein  $Q_1$  is (C=O),  $SO_2$  or (CN), provided when  $Q_1$  is CN, then X is absent;

wherein  $Q_3$  and  $Q_4$  are each independently O, S or NH;


wherein one of  $R_2$  and  $R_3$  is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e)  $R_a Q_2 R_b$  wherein  $Q_2$  is -O- or -S-; wherein  $R_a$  is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein  $R_b$  is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when  $R_b$  is 0, then  $R_b$  is a hydrogen atom;

wherein  $R_4$  is

- (a) H;
- (b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein  $R_5$  is



wherein  $Z_i$ ,  $Z_{ii}$ ,  $Z_{iii}$ ,  $Z_{iv}$  and  $Z_v$  are each independently selected from  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{C}(=\text{O})-\text{R}_1$ ,  $-\text{SO}_3\text{H}$ , a hydrogen atom, halogen, methyl,  $-\text{OR}_x$ , wherein  $\text{R}_x$  is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein  $\text{Y}_1$  is  $-\text{OH}$ , methyl,  $-\text{SH}$ , an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or  $\text{CH}_a\text{Z}_b$  where  $a+b=3$ ,  $a=0$  to 3,  $b=0$  to 3 and  $\text{Z}$  is cyano, nitro or a halogen;


wherein  $\text{R}_6$  is

- (a)  $\text{H}$ ;
- (b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein  $\text{T}$  is  $\text{O}$  or  $\text{S}$ , and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated superoxide generation or degranulation activity in a subject is modulated.

31. (Amended) A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:


a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein X is R<sub>1</sub>, OR<sub>1</sub>, or SR<sub>1</sub>;

wherein R<sub>1</sub> is

- (i) a hydrogen atom;
- (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight chain or branched;
- (iii) a cycloalkyl of 3 to 10 carbon atoms;
- (iv) an aralkyl of 7 to 12 carbon atoms;
- (v) phenyl;
- (vi) substituted phenyl



wherein Z<sub>i</sub>, Z<sub>ii</sub>, Z<sub>iii</sub>, Z<sub>iv</sub> and Z<sub>v</sub> are each independently selected from -NO<sub>2</sub>, -CN, -C(=O)-R<sub>1</sub>, -SO<sub>3</sub>H, a hydrogen atom, halogen, methyl, -OR<sub>x</sub>, wherein R<sub>x</sub> is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;

- (vii) a detectable label molecule; or

(viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;

wherein  $Q_1$  is (C=O),  $SO_2$  or (CN), provided when  $Q_1$  is CN, then X is absent;

wherein  $Q_3$  and  $Q_4$  are each independently O, S or NH;


wherein one of  $R_2$  and  $R_3$  is a hydrogen atom and the other is

- (a) H;
- (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
- (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
- (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or
- (e)  $R_a Q_2 R_b$  wherein  $Q_2$  is -O- or -S-; wherein  $R_a$  is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein  $R_b$  is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when  $R_b$  is 0, then  $R_b$  is a hydrogen atom;

wherein  $R_4$  is

- (a) H;
- (b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;

wherein  $R_5$  is



Application Number: 10/042,043

Docket: 7214.07

wherein  $Z_i$ ,  $Z_{ii}$ ,  $Z_{iii}$ ,  $Z_{iv}$  and  $Z_v$  are each independently selected from  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{C}(=\text{O})-\text{R}_1$ ,  $-\text{SO}_3\text{H}$ , a hydrogen atom, halogen, methyl,  $-\text{OR}_x$ , wherein  $\text{R}_x$  is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;

wherein  $\text{Y}_1$  is  $-\text{OH}$ , methyl,  $-\text{SH}$ , an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or  $\text{CH}_a\text{Z}_b$  where  $a+b=3$ ,  $a=0$  to 3,  $b=0$  to 3 and  $\text{Z}$  is cyano, nitro or a halogen;

wherein  $\text{R}_6$  is

- (a) H;
- (b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;

wherein  $\text{T}$  is O or S, and pharmaceutically acceptable salts thereof; and instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated superoxide generation or degranulation activity in the subject.

#### REMARKS

Claim 1 has been canceled.

Claims 23 and 31 have been amended to more particularly point out and distinctly claim the invention. No new subject matter has been added.

Claims 17 through 32 are pending.

No fees are considered due at this time, however, if a deficiency occurs, please charge our deposit account number 04-1420 to maintain pendency.